GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Deferred Tax

CLLS (Cellectis) Deferred Tax : $-0.54 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Cellectis's change in deferred tax for the three months ended in Dec. 2024 was $-0.03 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.54 Mil.

Cellectis Deferred Tax Historical Data

The historical data trend for Cellectis's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Deferred Tax Chart

Cellectis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.09 0.37 -0.54

Cellectis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.26 -0.19 -0.06 -0.03

Cellectis Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Deferred Tax Related Terms

Thank you for viewing the detailed overview of Cellectis's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Deferred Tax
Comparable Companies
XPAR:IPH XPAR:NANO XPAR:IVA XPAR:GNFT XPAR:OSE XPAR:ALSEN XPAR:DBV XPAR:TNG XPAR:MAAT XPAR:ADOC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0WA2:UK ALCLS:France ZVAA:Germany
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Website
https://www.cellectis.com
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.